Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
- PMID: 35643094
- DOI: 10.1016/S1473-3099(22)00294-8
Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
Conflict of interest statement
KK is employed by Cadila Healthcare. JJM is employed by the Medicines for Malaria Venture. All other authors declare no competing interests. GR and JG contributed equally. Cadila Healthcare and the Medicines for Malaria Venture funded the main clinical trial of ZY-19489, from which these exploratory data were obtained. The Medicines for Malaria Venture is supported by a grant from the Bill & Melinda Gates Foundation (grant number INV-007155). DSK and MR contributed equally to this Correspondence and share last authorship.
Comment on
-
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.Lancet Infect Dis. 2022 Jun;22(6):879-890. doi: 10.1016/S1473-3099(21)00679-4. Epub 2022 Mar 2. Lancet Infect Dis. 2022. PMID: 35247321 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources